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Abstract
Background: Inhaled corticosteroids (ICS) reduce exacerbation rates and improve health status but can increase the risk of
pneumonia in COPD. The GLUCOLD study, investigating patients with mild-to-moderate COPD, has shown that long-term
(2.5-year) ICS therapy induces anti-inflammatory effects. The literature suggests that cigarette smoking causes ICS
insensitivity. The aim of this study is to compare anti-inflammatory effects of ICS in persistent smokers and persistent ex-
smokers in a post-hoc analysis of the GLUCOLD study.
Methods: Persistent smokers (n = 41) and persistent ex-smokers (n = 31) from the GLUCOLD cohort were investigated.
Effects of ICS treatment compared with placebo were estimated by analysing changes in lung function, hyperresponsive-
ness, and inflammatory cells in sputum and bronchial biopsies during short-term (0–6 months) and long-term (6–30
months) treatment using multiple regression analyses.
Results: Bronchial mast cells were reduced by short-term and long-term ICS treatment in both smokers and ex-smokers. In
contrast, CD3+, CD4+, and CD8+ cells were reduced by short-term ICS treatment in smokers only. In addition, sputum
neutrophils and lymphocytes, and bronchial CD8+ cells were reduced after long-term treatment in ex-smokers only. No
significant interactions existed between smoking and ICS treatment.
Conclusion: Even in the presence of smoking, long-term ICS treatment may lead to anti-inflammatory effects in the lung.
Some anti-inflammatory ICS effects are comparable in smokers and ex-smokers with COPD, other effects are cell-specific.
The clinical relevance of these findings, however, are uncertain.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by chronic, partially reversible airflow limitation [1]. This airflow
limitation is generally progressive and associated with an
inflammatory process in the airways. The main cause for the
development of COPD is cigarette smoking. Smoking cessation is
the most effective way to reduce disease progression and to prevent
mortality [1]. Interestingly, inflammation is reduced in asymp-
tomatic smokers who stopped smoking [2]. In contrast, there is
evidence that airway inflammation persists or even increases in
COPD patients after smoking cessation [2,3].
Inhaled corticosteroids (ICS) have anti-inflammatory effects in
asthma. Clinical effects of ICS in COPD have been investigated
widely, providing positive effects on exacerbation rates and health
status especially in advanced stages [4–6], but also of harm (e.g.
pneumonia) [7]. The GLUCOLD study has shown that besides
positive effects on lung function decline, hyperresponsiveness and
health status, long-term (2.5-year) therapy with ICS additionally
induces anti-inflammatory effects in COPD patients with mild-to-
moderate severe disease [8]. Bronchial T-lymphocyte and mast
cell numbers were reduced after treatment as well as sputum cell
counts. Importantly, these anti-inflammatory effects were accom-
panied by a reduction in FEV1 decline and improvement in airway
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hyperresponsiveness and health status [8]. Other studies either
found no anti-inflammatory effects as assessed in sputum [9], or
confirmed anti-inflammatory effects of three-month ICS treatment
assessed in bronchial biopsies of COPD patients, including
reductions in CD8+ lymphocytes, mast cells and macrophages
[10–12].
There are several indications that cigarette smoking may induce
resistance to the anti-inflammatory effects of ICS. Smoking
asthmatics are less sensitive to corticosteroids than non-smoking
asthmatics [13–15]. One short-term study showed no anti-
inflammatory effects by ICS treatment in smokers with COPD,
whereas limited beneficial effects were observed in ex-smokers
[16]. In vitro studies have shown that oxidative and nitrative stress,
as can be caused by cigarette smoking, inactivates histone
deacetylase-2, which is involved in the suppression of activation
of inflammatory genes [17,18].
The GLUCOLD study provided evidence for both clinical and
anti-inflammatory effects of long-term ICS treatment in COPD.
So far, no studies have linked long-term clinical and inflammatory
effects of ICS treatment with active smoking in COPD. The aim of
the current study is to assess anti-inflammatory effects of ICS in
persistent smokers and persistent ex-smokers with COPD by a
post-hoc analysis of the GLUCOLD study.
Methods
Ethics Statement
The study was approved by the medical etics committee of
Leiden University Medical Center (LUMC) and by the medical
etics committee of University Medical Center Groningen
(UMCG). All patients signed written informed consent. The study
is registered at ClinicalTrials.gov with identifier NCT00158847.
Subjects
All persistent smokers and persistent ex-smokers from the
GLUCOLD cohort were included [8]. To obtain the largest
contrast possible, patients who switched in smoking status were
excluded. In- and exclusion criteria have been described in detail
previously [8]. Briefly, patients were aged 45–75 years, had a
smoking history of more than ten packyears, and irreversible
airflow limitation compatible with Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stages II and III [1]. Patients
with asthma or other active lung disease were excluded.
Study Design
Patients were randomly assigned into four groups as described
before [8]: 1) fluticasone propionate (FP) 500 mg twice daily (b.i.d.)
for the first six months, followed by placebo b.i.d. for 24 months; 2)
FP 500 mg b.i.d. for 30 months; 3) FP 500 mg b.i.d., and salmeterol
(S) 50 mg b.i.d. in a single inhaler for 30 months; 4) placebo b.i.d.
for 30 months.
Measurements
At baseline and after 6- and 30-month treatment, inflammatory
cells in induced sputum and bronchial biopsies, postbronchodi-
lator forced expiratory volume in one second (FEV1), and the
provocative concentration of metacholine causing a 20% fall in
FEV1 (PC20) were measured. Sputum samples were obtained by
the full sample method [19]. Differential cell counts were
expressed as a percentage of nucleated cells excluding squamous
cells as previously described [19]. Fiberoptic bronchoscopy, biopsy
processing and quantification were performed as described before
[3]. Immunohistochemistry was performed by specific antibodies
against T-lymphocytes (CD3, CD4, CD8), and mast cell tryptase
(AA1) [3]. The number of subepithelial positively staining
inflammatory cells was counted within the largest possible area
of maximal 125 mm deep beneath the basement membrane, per
biopsy section, and expressed as the mean number of cells/0.1
mm2 of the two biopsies [3]. FEV1 was assessed by standardized
procedures as well as the two-minute tidal breathing method to
measure PC20 methacholine [19].
Statistical Analyses
The absolute changes between the measurements at baseline
and 6 months, and between the measurements at 6 months and 30
months, were calculated for FEV1, PC20, and inflammatory cells
in sputum and bronchial biopsies. These absolute changes were
normalized by Ln-transformation when necessary. Multiple
regression analyses were performed on these (Ln-transformed)
absolute changes after short-term ICS treatment (baseline to 6
months) and after long-term ICS treatment (6 to 30 months). For
the analyses from baseline to 6 months, the FP 6-month, FP 30-
month, and FP/S 30-month groups were combined. For the
analyses from 6 to 30 months, the placebo group was combined
with the FP 6-month group, and the FP 30-month group was
combined with the FP/S 30-month group. The effects of ICS
treatment in persistent smokers and persistent ex-smokers and the
interaction of ICS with smoking were investigated in the total
population by multiple regression models. All models were
adjusted for gender and age. The analyses were performed with
SPSS version 18.0.3 and a p-value ,0.05 was considered
statistically significant.
Results
Of the 101 patients who adhered to therapy (.70% medication
use) [8], 72 patients who were persistent smokers (n = 41) and
persistent ex-smokers (n = 31) were included in the current
analyses. Characteristics of these 72 COPD patients among the
different treatment groups are shown in Table 1 including the
measurements at baseline, and after 6 or 30 months of ICS
treatment.
Short-term Effects
Multiple regression analyses showed that ICS treatment
increased PC20 significantly in ex-smokers (Table 2). ICS
treatment significantly reduced bronchial mast cells in both
smokers and ex-smokers compared to placebo. Additionally,
bronchial CD3+, CD4+, and CD8+ cells were significantly reduced
by ICS treatment in smokers only (Table 2).There were no
significant interactions between ICS treatment and smoking.
Long-term Effects
Stratified analyses showed significant reductions in bronchial
mast cells in both smokers and ex-smokers with ICS treatment
compared to placebo (Table 2, Figure 1). In contrast to smokers,
ex-smokers had significant reductions in bronchial CD8+ cells with
ICS treatment as well as sputum neutrophil counts (Table 2,
Figure 1). There existed no significant interactions between
smoking and ICS treatment (Table 2).
Discussion
This study investigated the confounding effect of concurrent
smoking with respect to the short- and long-term effects of ICS
treatment on clinical and inflammatory outcomes in persistent
smokers and persistent ex-smokers with COPD participating in the
GLUCOLD study. We did not find statistical interactions between
ICS Effects in Smokers and Ex-Smokers with COPD
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ICS treatment and smoking, implying that the effect of ICS
treatment on clinical and inflammatory parameters was compa-
rable in smokers and ex-smokers. Multiple regression analyses
showed that bronchial mast cell numbers significantly were
reduced both in persistent smokers and persistent ex-smokers.
This occurred with short- and long-term ICS treatment, showing
the robustness of this observation. Furthermore, a significant
reduction in number of bronchial CD8+ lymphocytes was
observed after long-term ICS treatment in ex-smokers only. This
is compatible with results in the main paper [8]. Additionally,
stratified analysis showed that sputum neutrophils were reduced
during long-term ICS treatment in ex-smokers only, a finding that
fits published studies on steroid responsiveness [12]. Bronchial
CD3+, CD4+, and CD8+ cells were reduced in smokers only after
short-term ICS treatment.
So far, studies investigating the effect of smoking on corticoste-
roid responsiveness have been performed in asthmatics predom-
inantly. Smoking asthmatics were shown to be less sensitive to
corticosteroids than non-smoking asthmatics [13–15]. There have
been less studies published investigating the effect of smoking on
corticosteroid responsiveness in COPD than in asthma. One short-
term study (10-week treatment) found no anti-inflammatory effects
of ICS treatment investigating inflammatory mediators like IL-8,
IL-10, neutrophil elastase in sputum in smokers with COPD,
whereas limited beneficial effects were present in ex-smokers [16].
In a study focusing on inflammation in airway wall biopsies, effects
of ICS+salmeterol treatment were in the same direction in smokers
and ex-smokers, although the reduction in cell counts (CD8+,
CD4+, CD45+, mast cells, CD68+) were generally greater in
former smokers [12]. Our data link, to our knowledge for the first
time, the effects of short-term and long-term ICS treatment to the
smoking status of patients with COPD. We show reductions
particularly in mast cells in both persistent smokers and persistent
ex-smokers, whereas other cell types were sometimes differentially
affected in these two groups.
We believe that the fact that we analysed patient groups
containing exclusively persistent smokers or persistent ex-smokers,
in addition to the long-term intervention and the combined
clinical and inflammatory outcomes represent the strengths of the
current study. There are some limitations as well. We did not find
significant interactions of ICS treatment response and smoking.
This can be a real observation, yet it may also be due to low
power, caused by the reduction in number of participants since we
excluded switchers in smoking status. This resulted in small
numbers in some subgroups, e.g. only 6 ex-smokers using ICS for
six months, and thus this asks for caution of providing firm
conclusions. For instance, there were differential effects with
regard to short- and long-term treatment effects on lymphocytes,
which may particularly result from analysing small numbers of
patients. However, the direction of effects of other cell types was
comparable with both short- and long-term follow-up providing
robust findings. Additionally, we have to take into account that
combining treatment groups in the 6–30 months period might
have affected the results, for example by the effect of steroid
withdrawal in the control group. However, when the individuals
who stopped FP after 6 months were excluded, the analyses
showed the same direction of effects and still reached significance
despite lower study power (Table S1). We realize that the current
study is the only one available with long-term biopsy data. There
may have occurred some selection bias due to the strict definition
of the patient groups. Notwithstanding this, the effects observed
were, with respect to clinical (PC20, FEV1) and inflammatory
parameters, in the same direction as the main results [8], and our
stratified analyses confirmed the multiple regression findings. One
may argue that there are baseline differences in cell counts in the
various groups under study. Therefore, we analysed our data with
Table 2. Multiple regression analyses: effects of ICS treatment in smokers and ex-smokers, and the interaction between ICS
treatment and smoking (smoking6ICS) on changes in lung function, hyperresponsiveness and inflammatory cells in biopsies and
sputum.*
0–6 months ICS treatment 6–30 months ICS treatment
Ex-smokers Smokers Smoking6ICS Ex-smokers Smokers Smoking6ICS
B p B p B p B p B p B p
FEV1, post, L 0.09 0.27 20.07 0.27 20.17 0.12 0.09 0.26 0.14 0.04 0.05 0.62
PC20, mg/mL 2.65 0.02 0.49 0.59 22.16 0.13 2.40 0.02 0.41 0.68 21.99 0.16
Bronchial cell counts`
CD3+ cells 20.66 0.13 20.92 0.01 20.27 0.63 20.71 0.11 0.36 0.39 1.07 0.08
CD4+ cells 20.86 0.07 21.37 0.00 20.51 0.40 20.03 0.94 0.34 0.44 0.37 0.55
CD8+ cells 20.55 0.21 20.70 0.05 20.15 0.79 21.08 0.02 20.03 0.96 1.06 0.11
Mast cells 20.83 0.00 20.50 0.04 0.33 0.37 21.36 0.00 20.67 0.04 0.69 0.17
Sputum cell counts1
Neutrophils 20.44 0.45 20.04 0.93 0.40 0.59 21.24 0.04 0.76 0.21 0.61 0.45
Eosinophils 21.55 0.12 0.25 0.74 1.80 0.15 0.39 0.67 20.60 0.44 20.98 0.41
Lymphocytes 20.14 0.85 20.08 0.89 0.06 0.95 21.30 0.13 21.33 0.08 20.03 0.98
Macrophages 20.39 0.53 0.17 0.73 0.55 0.48 1.05 0.95 213.99 0.34 215.03 0.49
*Patients were selected from the GLUCOLD cohort [8]; only persistent smokers and ex-smokers were included. All analyses are adjusted for age and sex. Data are
expressed as B, p (regression coefficient, p-value); significant data (p,0.05) are presented in bold; FEV1, post, L = FEV1 after salbutamol expressed in liters;
PC20 = provocative concentration of metacholine causing a fall in FEV1 of .20%;
`Cell counts/1027 per m2 of subepithelium;
1Cell counts6104 per mL. The absolute changes in bronchial cell counts and sputum cell counts were normalized by Ln-transformation.
doi:10.1371/journal.pone.0087443.t002
ICS Effects in Smokers and Ex-Smokers with COPD
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adjustment of baseline cell counts as well and found that results of
biopsy and sputum analyses were comparable. The (borderline)
significant effects of long-term ICS treatment on neutrophils in the
total group and ex-smokers became insignificant.
How can we explain that mast cell numbers were reduced by
short- and long-term ICS treatment in smokers and ex-smokers in
stratified analyses, whereas other cells were affected either in
smokers or ex-smokers, or not affected at all, as for instance
macrophages? One explanation may be that this reflects an
epigenetic phenomenon [20] that may occur with DNA methyl-
ation and histone modification. Histone deacetylase-2 can be
inactivated by oxidative and nitrative stress due to cigarette
smoking [17] thereby inducing chromatin condensation and
repression of gene transcription. In this way it can interfere with
the anti-inflammatory actions of inhaled corticosteroids. Epige-
netic regulation is known to be cell-specific and tissue-specific,
selectively inactivating genes and signal transduction pathways
[20]. This may thus explain differential effects of ICS in smokers
and ex-smokers in specific cell types.
Gizycki et al. found that mast cells were reduced with 3-month
ICS treatment in COPD patients who had high packyears
smoking and smoked on average 27 cigarettes per day [21],
corroborating our finding that mast cells are reduced by ICS
treatment in persistent smokers with COPD. This suggests that
epigenetic effects of smoking, if present, do not take place in mast
cells with respect to the ultimate effects of ICS treatment. We
found that bronchial CD8+ cells specifically were reduced in ex-
smokers after long-term ICS treatment. An in vitro study by Kaur
et al. on lymphocytes obtained by bronchoalveolar lavage in
COPD patients showed that dexamethasone reduced IL-2 and
INFgamma production after PHA/PMA stimulation [22]. Effects
were comparable in smokers and ex-smokers, suggesting that
activation of lymphocytes is steroid sensitive in COPD regardless
of smoking. We found that CD8 cells were significantly reduced by
long-term ICS treatment in ex-smokers and not in smokers with
COPD. Although, the interaction between smoking and ICS
treatment was not statistically significant, the estimated difference
between the ex-smokers and current smokers with respect to the
Figure 1. Effects of long-term ICS treatment on CD8+ cells and bronchial mast cells. Effects of ICS treatment from 6–30 months in
persistent smokers and persistent ex-smokers on bronchial CD8+ cells (upper panel) and bronchial mast cells (lower panel). Data are presented as
medians (Interquartile Ranges). NS =not significant.
doi:10.1371/journal.pone.0087443.g001
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ICS-effect is striking. Whether these seemingly different observa-
tions are due to the relatively low number of patients under study
in our investigation, to differential effects of steroids on lung influx
and activation of lymphocytes, or to differences in steroid
sensitivity when tested in all lymphocyte subtypes (as studied by
Kaur et al) versus the CD8 subset in our study has yet to be
determined. Our data together might reflect the idea that CD8+
cells, which are important key players in COPD, are sensitive to
e.g. histone modification induced by smoke exposure, whereas
mast cells are not.
We suggest that the clinical implication of our findings may be
that, even in the presence of smoking, long-term ICS treatment
may lead to anti-inflammatory effects in the lung. However,
especially in COPD patients with frequent exacerbations, the
balance between positive clinical and anti-inflammatory effects
and side effects (e.g. pneumonia [7]) still has to be considered. We
put forward the hypothesis that steroid unresponsiveness in COPD
is not a general characteristic. Some anti-inflammatory ICS effects
are comparable in smokers and ex-smokers with COPD, yet other
effects are cell-specific, dependent on smoking status. Studies in
larger datasets are needed to prospectively study the underlying
mechanisms of similar or differential ICS effects in smokers and
ex-smokers with COPD. This will open avenues for further
targeted therapy in persistent smokers and ex-smokers with
COPD.
Supporting Information
Table S1 Patients were selected from the GLUCOLD
cohort [7]; only persistent smokers and ex-smokers
were included. All analyses are adjusted for age and sex. Data
are expressed as B, p (regression coefficient, p-value); significant
data (p,0.05) are presented in bold; FEV1, post, L= FEV1 after
salbutamol expressed in liters; PC20 = provocative concentration of
metacholine causing a fall in FEV1 of .20%; { Cell counts/10
27
per m2 of subepithelium; 1 Cell counts6104 per mL. The absolute
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